Forrester, Ian S. and Dawes, Anthony (2008): Parallel Trade in Prescription Medicines in the European Union: The Age of Reason? Published in: Yearbook of Antitrust and Regulatory Studies , Vol. Volume, No. 1 (2008): pp. 9-31.
Download (314kB) | Preview
In light of the economic reality, which is increasingly confirmed by relevant judicial authorities, we submit that hindering parallel trade in prescription medicines does not damage patients and national health budgets. It is therefore to be welcomed that both Community and national case law has confirmed that pharmaceutical companies are entitled to adopt measures responding to – but not prohibiting or eliminating – parallel trade, and such measures are not contrary to the EC competition rules. Parallel traders had previously been free-riding on case law which referred to sectors and cases that bore no relation to the special features of the European prescription medicines sector. To the extent there is an assumption that parallel trade in Europe safeguards intra-brand competition, the recent case law does not call this assumption into question: on the contrary, it confirms it, while noting that this assumption is inapplicable to the prescription medicines sector in Europe precisely because of that sector’s very specific features. It is therefore to be hoped that the long-running obsession of European competition law with parallel trade in prescription medicines may (at last) be coming to an end.
|Item Type:||MPRA Paper|
|Original Title:||Parallel Trade in Prescription Medicines in the European Union: The Age of Reason?|
|Keywords:||prescription medicines, european union, competition law, market integration|
|Subjects:||K - Law and Economics > K2 - Regulation and Business Law > K21 - Antitrust Law|
|Depositing User:||Michał Mijal|
|Date Deposited:||21. Jul 2010 06:06|
|Last Modified:||13. Feb 2013 08:10|
Behrens H.-P., “Parallelhandelsbeschränkungen und Konsumentenwohlfahrt – Zur neueren Rechtsrechung von EuG und EuGH” (2008) 6 Zeitschrift für Wettbewerbsrecht.
Calvet H., “Commerce parallèle et droit européen: La fin d’un dogme ?” (2007) 10 Revue Lamy de la Concurrence.
Chalmers D., Hadjiemmanuil C., Monti. G. and Tomkins A., European Union Law, CUP Cambridge 2006.
Dawes A., “Neither Head nor Tail: The Confused Application of EC Competition Law to the Pharmaceutical Sector” (2006) 27 European Competition Law Review.
Dieny E., “Appréciation au regard du droit communautaire de la concurrence d’un accord visant à réduire le commerce parallèle des médicaments” (2006) JCP La Semaine Juridique.
Eccles R., “Parallel Exports in the Pharmaceuticals Sector: Take Nothing for Granted” (2007) 28 European Competition Law Review.
Forrester, I., “The Dangers of Too Much Precaution” [in:] M. Hoskins, W. Robinson (eds.), A True European: Essays for Judge David Edward, Oxford/Portland, 2003.
Forrester I., “The Repackaging of Trademarked Pharmaceuticals in Europe: Recent Developments,” paper presented at the Eighth Annual Conference on International Intellectual Property Law and Policy at Fordham University School of Law, April 2000, (2000) 11 European Intellectual Property Review.
Jenny F., “Pharmaceuticals, Competition and Free Movement of Goods” [in:] EU Competition Law and Policy, Developments and Priorities, Hellenic Competition Committee (ed.), Athens Conference, April 19th 2002, Athens, Nomiki Vivliothiki.
Junod V., “An End to Parallel Imports of Medicines? Comments on the Judgment of the Court of First Instance in GlaxoWellcome” (2007) 30 World Competition.
Korah V., Intellectual Property Rights and the EC Competition Rules, Oxford/Portland, 2006.
Korah V., “Judgment of the Court of First Instance in GlaxoSmithKline” (2007) 6 Competition Law Journal.
Köning C., Engelmann C., “Parallel Trade Restrictions in the Pharmaceutical Sector on the Test Stand of Article 82 EC: Commentary on the Opinion on Advocate General Jacobs in the Case Syfait/Glaxosmithkline”, (2005) 25 European Competition Law Review.
Nikpay A., Kjølbye L. and Faull J., “Article 81”, [in:] J. Faull, A. Nikpay (eds.), The EC Law of Competition, Oxford, 2007.
Rey P., Venit, J.S., “Parallel Trade and Pharmaceuticals: A Policy in Search of Itself” (2004) 29 European Law Review.
Roth W-H., “Möglichkeiten und Grenzen eines einheitlichen Binnenmarktes für Arzneimittel” [in:] J. Schwarze, U. Becker (eds.), Arzneimittel im Europäischen Binnenmarkt, Europarecht Beiheft 2/2007, Baden-Baden 2007.
Souto Soubrier L., “The Concept of an Agreement and Beyond: How to Block Parallel Imports of Pharmaceuticals to Protect the Heart of Competition” [in:] G. Amato, C.D.
Smits R., “On Parallel Trade and Preliminary Issues – A Healthy Approach to Competition Law Enforcement?” (2006) 33 Legal Issues of European Integration.
Ehlermann (eds.), EC Competition Law, A Critical Assessment, Oxford/Portland, 2007.
Stothers C., “Counterfeit Pharmaceuticals Enter The Parallel Supply Chain” (2007) 2 Journal of Intellectual Property Law & Practice.